Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,236 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,066
- Phase 1823
- Phase 1/Phase 2446
- Phase 3426
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis345
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama179
- Arizona141
- Florida141
- New York122
- Massachusetts120
- Texas119
- Illinois82
- Colorado77
Recruiting studies6,236 total
- NCT05700565Recruiting
Treating hard-to-treat immune side effects after immunotherapy
This trial studies a treatment called ECP to help immune-related side effects (irAEs) that did not improve with standard steroid treatment. It may help control symptoms and change immune activity to reduce ongoing harm from immunotherapy.
MunichAges Any age - NCT05732779Recruiting
App-based check-ins to help teens take transplant medicines
This study tests a phone app that uses video check-ins (called directly observed therapy) to help adolescent heart-transplant patients take their immunosuppression medicines as prescribed. It may help reduce missed doses, which is important for protecting the transplanted heart.
Coral Gables, FloridaAges 10–21 - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT05656105RecruitingEarly Phase 1
PET scan study of brain inflammation after COVID
This early-phase study uses a special PET scan to look for signs of brain inflammation in people with ongoing (long-term) nervous system symptoms after COVID-19. It may help researchers understand what is driving symptoms and whether this imaging approach can detect inflammation.
Birmingham, AlabamaAges 18–65 - NCT05645055Recruiting
Biologic treatment for bowel narrowing in Crohn’s disease
This trial studies biologic medicines to treat Crohn’s disease that causes bowel narrowing (“strictures”) without needing immediate surgery. It may help reduce symptoms and complications by targeting the immune-driven inflammation behind the narrowing.
Nanjing, JiangsuAges 16–65 - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05909436RecruitingPhase 1/Phase 2
Study GLS-012 for advanced solid tumors
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
BeijingAges 18–75 - NCT05481658RecruitingPhase 1
DPCP plus immunotherapy for skin cancer spread to the skin
This Phase 1 study tests a skin-applied treatment called DPCP added to standard PD-1/PD-L1 immunotherapy for cancers that have spread to the skin. It aims to improve control of skin tumors while checking safety and how well the immune system responds.
New York, New YorkAges 18 years+ - NCT05416307RecruitingPhase 2/Phase 3
ELA026 for secondary HLH after certain diagnostic findings
This study tests ELA026 (a new drug) in people with secondary HLH, a serious immune condition triggered by another illness or cause. It aims to see how well ELA026 works and how safe it is, using an open-label design where everyone knows they are getting the treatment.
Birmingham, AlabamaAges 6 years+ - NCT05600634Recruiting
Monitoring skin graft to spot rejection after kidney transplant
This study follows people after a kidney transplant to see if a small skin graft can help detect early signs of acute rejection. It may help your care team notice rejection sooner and adjust treatment earlier.
Xi'an, ShannxiAges 18–60 - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT05388682Recruiting
Treating Takayasu disease with lung artery involvement
This trial studies treatment for people with Takayasu arteritis when it affects the lung arteries. It may help reduce problems caused by narrowed or involved lung arteries.
BeijingAges Any age - NCT05462587RecruitingPhase 3
Test drug AVTX-803 for Leukocyte Adhesion Deficiency type II
This Phase 3 trial tests whether AVTX-803 can help prevent or improve infections in people with Leukocyte Adhesion Deficiency (LAD) type II. The study also checks how safe the drug is.
Rochester, MinnesotaAges 6 months–75 years - NCT05329935Recruiting
Registry for children with congenital thymus missing
This registry follows children born with congenital athymia (a missing or non-working thymus). It collects information around treatment with RETHYMIC, which may help researchers better understand how care and outcomes look over time.
Durham, North CarolinaAges birth–21 years - NCT05570552Recruiting
Testing health impacts in adults from smoky, arsenic-exposed homes
This study follows adults who took part in an earlier GEOHEALTH study and live in homes that use traditional stoves, with low-to-moderate arsenic exposure in drinking water. It aims to understand how these environmental factors affect health, and what changes might be possible.
DhakaAges 25–70 - NCT05426668Recruiting
Testing a blood-monitor device during lung cancer immunotherapy
This trial checks whether a device called TheraSure CNI-Monitor can be used while people with advanced lung cancer receive immunotherapy. It aims to improve monitoring during palliative (comfort-focused) treatment.
Göttingen, Lower SaxonyAges 18 years+ - NCT05392582Recruiting
Study tiny gene signals to calm inflammation with aging
This trial studies tiny gene-like signals (microRNAs) to understand and reduce long-term inflammation as people get older. It may help researchers learn how aging affects inflammation and could guide future treatments.
Salt Lake City, UtahAges 18 years+ - NCT05385432RecruitingPhase 3
Kidney transplant induction therapy for sensitized patients
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
ToursAges 18–79 - NCT05334940Recruiting
Care program for children and teens with multiple allergies
This trial is for people with moderate to severe allergic diseases who are about to start a biologic medicine (a targeted allergy treatment). It also looks at people who have more than one allergy condition, aiming to improve coordinated care across allergy problems.
BerlinAges 6 years+ - NCT05499637RecruitingPhase 2
PET/CT scan using a special tracer for heart inflammation
This Phase 2 study tests whether a PET/CT scan using a radioactive tracer can help evaluate acute heart inflammation. It may help doctors better identify inflammation and guide follow-up, especially in people suspected of specific heart inflammation conditions or recently after heart transplant follow-up.
Lausanne, Canton of VaudAges 18 years+ - NCT05319132Recruiting
Test a lab treatment for ROSAH syndrome using blood cells
This trial studies DF-003 in lab tests using blood immune cells taken from people with ROSAH syndrome. It aims to see whether the treatment works in lab “ex vivo” tests and could guide future options.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT05550298Recruiting
Study of virus infections after pediatric transplants
This study looks at how respiratory viruses behave and how the body responds in children who are about to receive, or have recently received, a transplant. It may help doctors better diagnose and treat viral infections in transplant patients by studying blood samples and test results.
Birmingham, AlabamaAges Up to 18 years - NCT05306080RecruitingEarly Phase 1
Rescue treatment for CAR T side effects in adults
This trial tests a rescue medicine given to treat severe immune over-reactions that can happen after CAR T cell therapy, such as cytokine release syndrome and an HLH-like syndrome. It may help calm the immune response if you are already enrolled in a specific CAR T study.
Philadelphia, PennsylvaniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,236 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,675 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.